Home  >  News  >  Details


PG2® Injection exhibits new therapeutic effects for stroke that once again amaze the world

Media report

PG2® Injection, a new drug marketed by PhytoHealth Corporation (4108), has exhibited an outstanding effect in a study on new indications for stroke. Chen Chun-Zhong (M.D., Department of Neurosurgery, China Medical University Hospital) accepted an invitation from the Asian Australasian Society of Neurological Surgeons (AASNS), the largest society of neurological surgeons in the world, to present the results at the Asian Australasian Congress of Neurological Surgeons (AACNS), held yesterday. He confirmed that PG2® Injection could reduce the incidence of moderate-to-severe disability by 30% in acute stroke patients after three months of administration. Because of the unavailability of effective treatment for this type of patients (unmet medical needs), PG2® Injection has gained great attention from international experts, reflecting its potential for the treatment of stroke.

AASNS and its 14,000 members consisting of world-renowned neurosurgeons hold a conference every four years. It is extremely rare for a new drug developed by a Taiwanese company, in this case PG2® Injection, to be presented at the AACNS.

According to the statistics of the Ministry of Health and Welfare (MOHW), Taiwan, stroke is the second leading cause of death after cancer in Taiwan, and it greatly affects the health of the Taiwanese population. Stroke is the leading cause of adult disability and the top three expenditures of health care resources. It causes different degrees of disability in patients, and most patients have a poor prognosis without the availability of an effective treatment, leading to a great burden for the family and society.

Chien-Hsin Cheng (Ph.D.), General Manager of PhytoHealth Corporation, has stated that PhytoHealth Corporation always looks forward to enhance stroke research and develop new indications for stroke for the benefit of patients worldwide.